Janney Capital Management LLC Raises Holdings in Structure Therapeutics Inc. (NASDAQ:GPCR)

Janney Capital Management LLC raised its stake in Structure Therapeutics Inc. (NASDAQ:GPCR) by 36.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,007 shares of the company’s stock after purchasing an additional 2,405 shares during the period. Janney Capital Management LLC’s holdings in Structure Therapeutics were worth $244,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also made changes to their positions in GPCR. Bank of Montreal Can acquired a new position in Structure Therapeutics in the second quarter valued at approximately $1,064,000. Vestal Point Capital LP lifted its position in shares of Structure Therapeutics by 105.4% during the 3rd quarter. Vestal Point Capital LP now owns 1,150,000 shares of the company’s stock worth $50,474,000 after buying an additional 590,000 shares during the last quarter. Lighthouse Investment Partners LLC acquired a new position in shares of Structure Therapeutics in the 2nd quarter valued at $1,178,000. abrdn plc boosted its holdings in shares of Structure Therapeutics by 132.7% in the 3rd quarter. abrdn plc now owns 217,083 shares of the company’s stock valued at $9,528,000 after buying an additional 123,789 shares in the last quarter. Finally, Barclays PLC grew its position in shares of Structure Therapeutics by 64.5% in the 3rd quarter. Barclays PLC now owns 81,138 shares of the company’s stock valued at $3,562,000 after buying an additional 31,815 shares during the last quarter. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on GPCR shares. Stifel Nicolaus initiated coverage on shares of Structure Therapeutics in a research report on Wednesday, January 8th. They issued a “buy” rating and a $50.00 price target for the company. HC Wainwright reissued a “buy” rating and issued a $80.00 target price on shares of Structure Therapeutics in a research report on Thursday, December 19th. Finally, JMP Securities restated a “market outperform” rating and set a $91.00 price target on shares of Structure Therapeutics in a research note on Wednesday, December 18th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $81.29.

Structure Therapeutics Stock Down 1.4 %

NASDAQ GPCR opened at $27.94 on Thursday. The firm has a market cap of $1.60 billion, a P/E ratio of -37.76 and a beta of -2.78. Structure Therapeutics Inc. has a 52-week low of $23.50 and a 52-week high of $62.74. The business’s 50-day moving average price is $30.38 and its 200 day moving average price is $35.89.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.